Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Surgery Partners, Inc. (NASDAQ: SGRY) is being taken private by Bon Secours Mercy Health, Inc. Surgery Partners is incorporated in Delaware.
If you are a current stockholder of Surgery Partners, Inc., you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/surgery-partners-merger-investigation.
Key Details of the Surgery Partners ($SGRY) Investigation:
- Investigation Overview: Breaches of Fiduciary Duty in connection with the merger in which Surgery Partners’ largest stockholder, Bain Capital, is rolling over their equity, but all other stockholders are being cashed out for $23.50 per share.
- Action: Contact BFA Law to discuss your rights
Why is the Surgery Partners Transaction being Investigated?
In the October 26, 2026 announcement of the merger, Surgery Partners disclosed that it was being taken private by Bon Secours Mercy Health, Inc., for a price of $23.50 per share. At the same time, the company disclosed that Bain Capital would be rolling over its equity into the post-merger entity. Bain Capital currently owns 39% of the company’s outstanding shares.
Surgery Partners has reported that the decision to enter into the merger was approved by a special committee of its board of directors, and the merger is conditioned on the majority approval of the minority stockholders. While Bain Capital’s ownership of the enterprise will continue, public stockholders have no opportunity to continue owning Surgery Partners after the merger.
BFA is investigating whether the terms of the merger comply with Delaware law, including whether Bain Capital’s self-interest in the merger caused related breaches of fiduciary duty, and whether the per share price is a fair price for the public stockholders’ shares of Surgery Partners stock.
Click here for more information:
https://www.bfalaw.com/cases/surgery-partners-merger-investigation
What Can You Do?
If you are a current holder of Surgery Partners stock, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases/surgery-partners-merger-investigation
Or contact:
Adam McCall
adam@bfalaw.com
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/surgery-partners-merger-investigation
Attorney advertising. Past results do not guarantee future outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261027093919/en/
Media gallery
